Share：
Share this content in WeChat
X
[Chinese][PDF]82924
• Review •
Application progress of MRI-T2 mapping in tumor
ZHAO Bo  SHI Yanjie  SUN Yingshi 

Cite this article as: Zhao B, Shi YJ, Sun YS. Application progress of MRI-T2 mapping in tumor[J]. Chin J Magn Reson Imaging, 2022, 13(7): 167-170. DOI:10.12015/issn.1674-8034.2022.07.034.


[Abstract] MRI is of important value to the diagnosis of tumor diseases due to its multiple planes, multiple sequences, high resolution, etc. With the precision of tumor diagnosis and treatment, quantitative evaluation of tumor image has gradually become a research focus. T2 mapping is a method for quantitative analysis of T2 values in tissues at the voxel level. Color maps corresponding to space can be generated through post-processing which reflect the T2 values in different colors to improve the objectivity and intuition of observation. The changes of T2 value can be caused by the density of benign and malignant tumor tissues, edema and necrosis during tumor treatment. Therefore, T2 mapping has high clinical application value. This article reviews the progress about quantitative research of T2 mapping in tumors.
[Keywords] magnetic resonance imaging；T2 mapping；breast cancer；prostate cancer；gliomas；rectal cancer

ZHAO Bo   SHI Yanjie   SUN Yingshi*  

Key Laboratory of Carcinogenesis and Translational Research [Ministry of Education]/Department of Radiology, Peking University Cancer Hospital & Institute, Beijing 100142, China

Sun YS, E-mail: sunysabc@163.com

Conflicts of interest   None.

Received  2022-03-28
Accepted  2022-06-24
DOI: 10.12015/issn.1674-8034.2022.07.034
Cite this article as: Zhao B, Shi YJ, Sun YS. Application progress of MRI-T2 mapping in tumor[J]. Chin J Magn Reson Imaging, 2022, 13(7): 167-170. DOI:10.12015/issn.1674-8034.2022.07.034.

[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]
Vermes E, Pantaléon C, Auvet A, et al. Cardiovascular magnetic resonance in heart transplant patients: diagnostic value of quantitative tissue markers: T2 mapping and extracellular volume fraction, for acute rejection diagnosis[J]. J Cardiovasc Magn Reson, 2018, 20(1): 59. DOI: 10.1186/s12968-018-0480-9.
[3]
Giri S, Chung YC, Merchant A, et al. T2 quantification for improved detection of myocardial edema[J]. J Cardiovasc Magn Reson, 2009, 11: 56. DOI: 10.1186/1532-429X-11-56.
[4]
Sabouri S, Chang SD, Savdie R, et al. Luminal water imaging: a new MR imaging T2 mapping technique for prostate cancer diagnosis[J]. Radiology, 2017, 284(2): 451-459. DOI: 10.1148/radiol.2017161687.
[5]
Liu L, Yin B, Shek K, et al. Role of quantitative analysis of T2 relaxation time in differentiating benign from malignant breast lesions[J]. J Int Med Res, 2018, 46(5): 1928-1935. DOI: 10.1177/0300060517721071.
[6]
Meng TB, He N, He HQ, et al. The diagnostic performance of quantitative mapping in breast cancer patients: a preliminary study using synthetic MRI[J]. Cancer Imaging, 2020, 20(1): 88. DOI: 10.1186/s40644-020-00365-4.
[7]
Carter JS, Koopmeiners JS, Kuehn-Hajder JE, et al. Quantitative multiparametric MRI of ovarian cancer[J]. J Magn Reson Imaging, 2013, 38(6): 1501-1509. DOI: 10.1002/jmri.24119.
[8]
Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging: multivariate analysis[J]. Radiology, 2000, 214(1): 39-46. DOI: 10.1148/radiology.214.1.r00ja3939.
[9]
Tian SF, Liu AL, Meng X, et al. The value of amide proton transfer imaging and T2 mapping imaging technology in differentiation stage Ⅰ endometrial carcinoma and endometrial polyp[J]. J Clin Radiol, 2021, 40(9): 1832-1835. DOI: 10.13437/j.cnki.jcr.2021.09.036.
[10]
Sabouri S, Fazli L, Chang SD, et al. MR measurement of luminal water in prostate gland: quantitative correlation between MRI and histology[J]. J Magn Reson Imaging, 2017, 46(3): 861-869. DOI: 10.1002/jmri.25624.
[11]
Mai JL, Abubrig M, Lehmann T, et al. T2 mapping in prostate cancer[J]. Invest Radiol, 2019, 54(3): 146-152. DOI: 10.1097/RLI.0000000000000520.
[12]
Klingebiel M, Schimmöller L, Weiland E, et al. Value of T2 mapping MRI for prostate cancer detection and classification[J/OL]. J Magn Reson Imaging, 2022 [2022-03-28]. https://onlinelibrary.wiley.com/doi/10.1002/jmri.28061. DOI: 10.1002/jmri.28061.
[13]
van Houdt PJ, Agarwal HK, van Buuren LD, et al. Performance of a fast and high-resolution multi-echo spin-echo sequence for prostate T2 mapping across multiple systems[J]. Magn Reson Med, 2018, 79(3): 1586-1594. DOI: 10.1002/mrm.26816.
[14]
Lee CH. Quantitative T2-mapping using MRI for detection of prostate malignancy: a systematic review of the literature[J]. Acta Radiol, 2019, 60(9): 1181-1189. DOI: 10.1177/0284185118820058.
[15]
Hepp T, Kalmbach L, Kolb M, et al. T2 mapping for the characterization of prostate lesions[J]. World J Urol, 2022, 40(6): 1455-1461. DOI: 10.1007/s00345-022-03991-8.
[16]
Wu LM, Yao QY, Zhu J, et al. T2* mapping combined with conventional T2-weighted image for prostate cancer detection at 3.0T MRI: a multi-observer study[J]. Acta Radiol, 2017, 58(1): 114-120. DOI: 10.1177/0284185116633916.
[17]
Lee CH, Taupitz M, Asbach P, et al. Clinical utility of combined T2-weighted imaging and T2-mapping in the detection of prostate cancer: a multi-observer study[J]. Quant Imaging Med Surg, 2020, 10(9): 1811-1822. DOI: 10.21037/qims-20-222.
[18]
Sathiadoss P, Schieda N, Haroon M, et al. Utility of quantitative T2-mapping compared to conventional and advanced diffusion weighted imaging techniques for multiparametric prostate MRI in men with hip prosthesis[J]. J Magn Reson Imaging, 2022, 55(1): 265-274. DOI: 10.1002/jmri.27803.
[19]
Cieszanowski A, Szeszkowski W, Golebiowski M, et al. Discrimination of benign from malignant hepatic lesions based on their T2-relaxation times calculated from moderately T2-weighted turbo SE sequence[J]. Eur Radiol, 2002, 12(9): 2273-2279. DOI: 10.1007/s00330-002-1366-6.
[20]
Cieszanowski A, Anysz-Grodzicka A, Szeszkowski W, et al. Characterization of focal liver lesions using quantitative techniques: comparison of apparent diffusion coefficient values and T2 relaxation times[J]. Eur Radiol, 2012, 22(11): 2514-2524. DOI: 10.1007/s00330-012-2519-x.
[21]
Wen BH, Cheng JL, Zhang Y, et al. MR transverse relaxation time imaging for differential diagnosis of benign and malignant parotid gland tumors[J]. Chin J Med Imaging Technol, 2021, 37(8): 1140-1144. DOI: 10.13929/j.issn.1003-3289.2021.08.005.
[22]
Zhou Y, Xu XQ, Hu H, et al. T2 mapping in orbital masses: preliminary study on differential diagnostic ability of T2 relaxation time[J]. Acta Radiol, 2020, 61(5): 668-674. DOI: 10.1177/0284185119874476.
[23]
Ge YX, Hu SD, Wang Z, et al. Feasibility and reproducibility of T2 mapping and DWI for identifying malignant lymph nodes in rectal cancer[J]. Eur Radiol, 2021, 31(5): 3347-3354. DOI: 10.1007/s00330-020-07359-7.
[24]
Xie JP, Zhang WD, Zhu JY, et al. The clinical value of T1 and T2 values in predicting brain glioma grading and cell proliferation activity[J]. Chin J Magn Reson Imaging, 2021, 12(1): 15-20. DOI: 10.12015/issn.1674-8034.2021.01.004.
[25]
Wang JN, Zhu JY, Zhang B, et al. The study of T1 and T2 values in differentiating of benign and malignant gliomas[J]. Chin J Magn Reson Imaging, 2020, 11(6): 416-421. DOI: 10.12015/issn.1674-8034.2020.06.004.
[26]
Kern M, Auer TA, Picht T, et al. T2 mapping of molecular subtypes of WHO grade Ⅱ/Ⅲ gliomas[J]. BMC Neurol, 2020, 20(1): 8. DOI: 10.1186/s12883-019-1590-1.
[27]
Gu WB, Fang SY, Hou XY, et al. Exploring diagnostic performance of T2 mapping in diffuse glioma grading[J]. Quant Imaging Med Surg, 2021, 11(7): 2943-2954. DOI: 10.21037/qims-20-916.
[28]
Li SJ, Cheng JL, Zhang Y, et al. Quantitative analysis of T2 mapping in evaluating pathological features of cervical cancer[J]. Chin J Med Imaging Technol, 2019, 35(9): 1365-1369. DOI: 10.13929/j.1003-3289.201903113.
[29]
Li SJ, Liu J, Zhang FF, et al. Novel T2 mapping for evaluating cervical cancer features by providing quantitative T2 maps and synthetic morphologic images: a preliminary study[J]. J Magn Reson Imaging, 2020, 52(6): 1859-1869. DOI: 10.1002/jmri.27297.
[30]
Li SJ, Zhang ZX, Liu J, et al. The feasibility of a radial turbo-spin-echo T2 mapping for preoperative prediction of the histological grade and lymphovascular space invasion of cervical squamous cell carcinoma[J]. Eur J Radiol, 2021, 139: 109684. DOI: 10.1016/j.ejrad.2021.109684.
[31]
Ma CJ, Liu AL, Tian SF, et al. Preliminary study of APT combined with T2 mapping sequence in preoperative risk assessment of endometrial carcinoma[J]. Chin J Magn Reson Imaging, 2021, 12(9): 69-72. DOI: 10.12015/issn.1674-8034.2021.09.016.
[32]
Hoang Dinh A, Souchon R, Melodelima C, et al. Characterization of prostate cancer using T2 mapping at 3T: a multi-scanner study[J]. Diagn Interv Imaging, 2015, 96(4): 365-372. DOI: 10.1016/j.diii.2014.11.016.
[33]
Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla[J]. Invest Radiol, 2009, 44(9): 572-576. DOI: 10.1097/RLI.0b013e3181b4c10e.
[34]
Adams LC, Bressem KK, Jurmeister P, et al. Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results[J]. Cancer Imaging, 2019, 19(1): 35. DOI: 10.1186/s40644-019-0222-8.
[35]
Zhang JQ, Ge YX, Zhang H, et al. Quantitative T2 mapping to discriminate mucinous from nonmucinous adenocarcinoma in rectal cancer: comparison with diffusion-weighted imaging[J/OL]. Magn Reson Med Sci, 2021 [2022-03-28]. https://www.jstage.jst.go.jp/article/mrms/advpub/0/advpub_mp.2021-0067/_article. DOI: 10.2463/mrms.mp.2021-0067.
[36]
Ghosh A, Singh T, Bagga R, et al. T2 relaxometry mapping in demonstrating layered uterine architecture: parameter optimization and utility in endometrial carcinoma and adenomyosis: a feasibility study[J/OL]. Br J Radiol, 2018, 91(1081) [2022-03-28]. https://www.birpublications.org/doi/10.1259/bjr.20170377. DOI: 10.1259/bjr.20170377.
[37]
Wei Y, Wu S, Gao FF, et al. Esophageal carcinoma: Ex vivo evaluation by high-spatial-resolution T2-mapping MRI compared with histopathological findings at 3.0T[J]. J Magn Reson Imaging, 2017, 45(6): 1609-1616. DOI: 10.1002/jmri.25509.
[38]
Yamada I, Yoshino N, Hikishima K, et al. Colorectal carcinoma: Ex vivo evaluation using 3-T high-spatial-resolution quantitative T2 mapping and its correlation with histopathologic findings[J]. Magn Reson Imaging, 2017, 38: 174-181. DOI: 10.1016/j.mri.2016.12.028.
[39]
Liu L, Yin B, Geng DY, et al. Changes of T2 relaxation time from neoadjuvant chemotherapy in breast cancer lesions[J/OL]. Iran J Radiol, 2016, 13(3) [2022-03-28]. https://brieflands.com/articles/iranjradiol-18060.html. DOI: 10.5812/iranjradiol.24014.
[40]
Tan PC, Pickles MD, Lowry M, et al. Lesion T(2) relaxation times and volumes predict the response of malignant breast lesions to neoadjuvant chemotherapy[J]. Magn Reson Imaging, 2008, 26(1): 26-34. DOI: 10.1016/j.mri.2007.04.002.
[41]
Hattingen E, Jurcoane A, Daneshvar K, et al. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival[J]. Neuro Oncol, 2013, 15(10): 1395-1404. DOI: 10.1093/neuonc/not105.

PREV Research progress of focal cortical dysplasia with FLAIR-negative of magnetic resonance imaging
NEXT Dynamic functional connectivity analysis of stable and progressive mild cognitive impairment
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn